Cargando…
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in S...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269707/ https://www.ncbi.nlm.nih.gov/pubmed/28000426 http://dx.doi.org/10.1002/cam4.985 |
_version_ | 1782501045430124544 |
---|---|
author | Lim, Li Yan Miao, Hui Lim, Joline S. J. Lee, Soo Chin Bhoo‐Pathy, Nirmala Yip, Cheng Har Taib, Nur Aishah B. M. Chan, Patrick Tan, Ern Yu Lim, Swee Ho Lim, Geok Hoon Woo, Evan Tan, Yia Swam Lee, Jung Ah Wong, Mabel Tan, Puay Hoon Ong, Kong Wee Wong, Fuh Yong Yap, Yoon Sim Hartman, Mikael |
author_facet | Lim, Li Yan Miao, Hui Lim, Joline S. J. Lee, Soo Chin Bhoo‐Pathy, Nirmala Yip, Cheng Har Taib, Nur Aishah B. M. Chan, Patrick Tan, Ern Yu Lim, Swee Ho Lim, Geok Hoon Woo, Evan Tan, Yia Swam Lee, Jung Ah Wong, Mabel Tan, Puay Hoon Ong, Kong Wee Wong, Fuh Yong Yap, Yoon Sim Hartman, Mikael |
author_sort | Lim, Li Yan |
collection | PubMed |
description | We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between pCR and clinicopathologic characteristics and treatment were evaluated using chi‐square test and multivariable logistic regression. Kaplan–Meier analysis and log‐rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved pCR and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50 years. pCR rates were 18.1% (pCR ypT0/is) and 14.4% (pCR ypT0/is ypN0), respectively. pCR rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2‐positive disease or receiving taxane‐based neoadjuvant chemotherapy. Patients who achieved pCR had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor‐negative tumors. Patients with poor prognostic profile are more likely to achieve pCR and particularly when receiving taxane‐containing chemotherapy. pCR is a significant prognostic factor for overall survival especially in estrogen receptor‐negative breast cancers. |
format | Online Article Text |
id | pubmed-5269707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52697072017-02-01 Outcome after neoadjuvant chemotherapy in Asian breast cancer patients Lim, Li Yan Miao, Hui Lim, Joline S. J. Lee, Soo Chin Bhoo‐Pathy, Nirmala Yip, Cheng Har Taib, Nur Aishah B. M. Chan, Patrick Tan, Ern Yu Lim, Swee Ho Lim, Geok Hoon Woo, Evan Tan, Yia Swam Lee, Jung Ah Wong, Mabel Tan, Puay Hoon Ong, Kong Wee Wong, Fuh Yong Yap, Yoon Sim Hartman, Mikael Cancer Med Clinical Cancer Research We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (pCR) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. pCR following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between pCR and clinicopathologic characteristics and treatment were evaluated using chi‐square test and multivariable logistic regression. Kaplan–Meier analysis and log‐rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved pCR and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50 years. pCR rates were 18.1% (pCR ypT0/is) and 14.4% (pCR ypT0/is ypN0), respectively. pCR rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2‐positive disease or receiving taxane‐based neoadjuvant chemotherapy. Patients who achieved pCR had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor‐negative tumors. Patients with poor prognostic profile are more likely to achieve pCR and particularly when receiving taxane‐containing chemotherapy. pCR is a significant prognostic factor for overall survival especially in estrogen receptor‐negative breast cancers. John Wiley and Sons Inc. 2016-12-20 /pmc/articles/PMC5269707/ /pubmed/28000426 http://dx.doi.org/10.1002/cam4.985 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Lim, Li Yan Miao, Hui Lim, Joline S. J. Lee, Soo Chin Bhoo‐Pathy, Nirmala Yip, Cheng Har Taib, Nur Aishah B. M. Chan, Patrick Tan, Ern Yu Lim, Swee Ho Lim, Geok Hoon Woo, Evan Tan, Yia Swam Lee, Jung Ah Wong, Mabel Tan, Puay Hoon Ong, Kong Wee Wong, Fuh Yong Yap, Yoon Sim Hartman, Mikael Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title_full | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title_fullStr | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title_full_unstemmed | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title_short | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
title_sort | outcome after neoadjuvant chemotherapy in asian breast cancer patients |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269707/ https://www.ncbi.nlm.nih.gov/pubmed/28000426 http://dx.doi.org/10.1002/cam4.985 |
work_keys_str_mv | AT limliyan outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT miaohui outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT limjolinesj outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT leesoochin outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT bhoopathynirmala outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT yipchenghar outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT taibnuraishahbm outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT chanpatrick outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT tanernyu outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT limsweeho outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT limgeokhoon outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT wooevan outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT tanyiaswam outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT leejungah outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT wongmabel outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT tanpuayhoon outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT ongkongwee outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT wongfuhyong outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT yapyoonsim outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients AT hartmanmikael outcomeafterneoadjuvantchemotherapyinasianbreastcancerpatients |